Comparative Pharmacology
Head-to-head clinical analysis: DELALUTIN versus NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELALUTIN versus NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
DELALUTIN vs NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium. Ethinyl estradiol is an estrogen that provides cycle control and contributes to contraceptive efficacy. Ferrous fumarate provides iron supplementation.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol, and 75 mg ferrous fumarate) orally once daily for 28 days, without interruption. Take the first tablet on the first day of menstrual bleeding.
None Documented
None Documented
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Norethindrone: 8-11 hours (terminal). Ethinyl estradiol: 10-20 hours (terminal). Clinical context: Steady-state achieved after 5-7 days; half-life supports once-daily dosing.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Norethindrone acetate and ethinyl estradiol are primarily excreted in urine (40-60% as metabolites) and feces (20-40% as metabolites). Ferrous fumarate is absorbed and iron is utilized; unabsorbed iron is excreted in feces.
Category C
Category D/X
Progestin
Progestin